News Releases

Investors

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Top

External Link

You are now leaving the Jasper Therapeutics, Inc. site to a 3rd party website. Jasper Therapeutics is not responsible for 3rd party website content.